TTY Biopharm Company Limited (TPEX:4105)

TTY Biopharm Company Revenue

TTY Biopharm Company had revenue of 1.65B TWD in the quarter ending June 30, 2026, with 9.23% growth. This brings the company's total for the last twelve months to 6.65B, up 7.04% year-over-year. In the year 2025, TTY Biopharm Company had annual revenue of 6.45B with 9.49% growth. That makes TTY Biopharm Company the 17,302nd largest company in the world by revenue and 615th in Taiwan.

• Revenue (ttm): 6.65B
• Revenue Growth: +7.04%
• P/S Ratio: 3.01
• Revenue / Employee: 19.46M
• Employees: 342
• Market Cap: 20.09B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Oncology Business Unit 2.50B 36.0%
• Intensive Care Business Unit 1.50B 21.5%
• Re-investment Business Unit 1.43B 20.5%
• Export and CDMO Business Unit 1.25B 17.9%
• Healthcare Unit 263.43M 3.8%
• Other Business Unit 21.92M 0.3%

By Geography

Chart

• Taiwan 5.49B 85.1%
• America 557.54M 8.6%
• Other Countries 405.11M 6.3%

Fiscal year ended Dec 31, 2025 See the full TTY Biopharm Company breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.45B	559.10M	9.49%
Dec 31, 2024	5.89B	388.31M	7.05%
Dec 31, 2023	5.51B	443.94M	8.77%
Dec 31, 2022	5.06B	526.00M	11.60%
Dec 31, 2021	4.54B	313.77M	7.43%

Data Source: S&P Global Market Intelligence Last updated: Aug 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error